Bart Keymeulen

13PUBLICATIONS
68CO-AUTHORS
BiomaterialsPredictive and prognostic markersDecision makingSolid tumoursGene expression (incl. microarray and other genome-wide approaches)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Aug 14, 2026
Markers of beta cell and alpha cell mass in human stem cell-generated implants with glycemic control at human setpoint.

|Feb 11, 2025
Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development.

Peter Calhoun, Charles Spanbauer, Andrea K Steck

|Feb 04, 2025
Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis.

Aster K Desouter, Bart Keymeulen, Ursule Van de Velde

|Nov 27, 2023
Encapsulated stem cell-derived β cells exert glucose control in patients with type 1 diabetes.

Bart Keymeulen, Kaat De Groot, Daniel Jacobs-Tulleneers-Thevissen

|Jan 09, 2023
CTLA4, SH2B3, and CLEC16A diversely affect the progression of early islet autoimmunity in relatives of Type 1 diabetes patients.

Julie Vandewalle, Aster K Desouter, Bart J Van der Auwera

|May 19, 2022
Ladarixin, an inhibitor of the interleukin-8 receptors CXCR1 and CXCR2, in new-onset type 1 diabetes: A multicentre, randomized, double-blind, placebo-controlled trial.

Lorenzo Piemonti, Bart Keymeulen, Pieter Gillard

Pageof 3

Frequent Collaborators

8 joint publications

Pieter Gillard

5 joint publications

Diedert Luc De Paep

5 joint publications

Frans K Gorus

5 joint publications

Daniel Pipeleers